What happened Shares of Dynavax Technologies (NASDAQ: DVAX) were jumping 11.4% as of 11:13 a.m. EDT on Friday after the company announced that the first participants have been dosed in a phase 1 study evaluating Clover Biopharmaceuticals' COVID-19 vaccine SCB-2019. The vaccine contains Dynavax's CpG 1018 adjuvant to boost immune responses. So what Investors continue to be intensely interested in the prospects for COVID-19 vaccines. Nearly any announcement of progress with coronavirus vaccine development is a catalyst for the biotech stocks involved. That's what happened with Dynavax today. Image source: Getty Images. To be sure, any good news for SCB-2019 is good news for Dynavax. The biotech signed a deal in March with Clover, a private company, to evaluate SCB-2019 with Dynavax's CpG 1018 adjuvant. While SCB-2019 is unproven at this point, CpG 2018 isn't. The adjuvant is already used with Dynavax's Heplisav-B hepatitis B vaccine. It's still very early, though. Clover and Dynavax have a long way to go before SCB-2019 can be declared a success. Meanwhile, there are 13 other coronavirus vaccine candidates already in clinical testing, with at least three of them in phase 2 studies, putting them well ahead of Clover and Dynavax. Now what Dynavax stated that preliminary results from Clover's phase 1 study should be available in August. Investors will certainly want to closely watch how promising the results for SCB-2019 are. Dynavax's CpG 2018 adjuvant is also being used in three other experimental COVID-19 vaccines. 10 stocks we like better than Dynavax TechnologiesWhen investing geniuses David and Tom Gardner have a stock tip, it can pay to listen. After all, the newsletter they have run for over a decade, Motley Fool Stock Advisor, has tripled the market.* David and Tom just revealed what they believe are the ten best stocks for investors to buy right now... and Dynavax Technologies wasn't one of them! That's right -- they think these 10 stocks are even better buys. See the 10 stocks *Stock Advisor returns as of June 2, 2020 Keith Speights has no position in any of the stocks mentioned. The Motley Fool has no position in any of the stocks mentioned. The Motley Fool has a disclosure policy.Source